257 related articles for article (PubMed ID: 21516323)
1. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.
Singh S; Tang SJ; Sreenarasimhaiah J; Lara LF; Siddiqui A
Dig Dis Sci; 2011 Aug; 56(8):2491-6. PubMed ID: 21516323
[TBL] [Abstract][Full Text] [Related]
2. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
[TBL] [Abstract][Full Text] [Related]
3. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
[TBL] [Abstract][Full Text] [Related]
4. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.
La Greca G; Sofia M; Lombardo R; Latteri S; Ricotta A; Puleo S; Russello D
World J Gastroenterol; 2012 Aug; 18(31):4150-5. PubMed ID: 22919247
[TBL] [Abstract][Full Text] [Related]
5. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
6. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
7. [The value of CA19-9 and CEA in predicting resectability of hilar cholangiocarcinoma].
Zong D; Zeng Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Sep; 45(5):819-22. PubMed ID: 25341348
[TBL] [Abstract][Full Text] [Related]
8. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
[TBL] [Abstract][Full Text] [Related]
9. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.
Qin XL; Wang ZR; Shi JS; Lu M; Wang L; He QR
World J Gastroenterol; 2004 Feb; 10(3):427-32. PubMed ID: 14760772
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
[TBL] [Abstract][Full Text] [Related]
11. High Bile Titer and High Bile to Serum Ratio of CYFRA 21 - 1 Reliably Discriminate Malignant Biliary Obstruction Caused by Cholangiocarcinoma.
Chen J; Liang J; Xu B; Liang J; Ma M; Wang Z; Zeng G; Xu Q; Liang L; Lai J; Huang L
J Gastrointest Cancer; 2024 Jun; 55(2):800-808. PubMed ID: 38280173
[TBL] [Abstract][Full Text] [Related]
12. Tumor markers as a diagnostic key for hilar cholangiocarcinoma.
Juntermanns B; Radunz S; Heuer M; Hertel S; Reis H; Neuhaus JP; Vernadakis S; Trarbach T; Paul A; Kaiser GM
Eur J Med Res; 2010 Aug; 15(8):357-61. PubMed ID: 20947473
[TBL] [Abstract][Full Text] [Related]
13. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
14. CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation.
Fisher A; Theise ND; Min A; Mor E; Emre S; Pearl A; Schwartz ME; Miller CM; Sheiner PA
Liver Transpl Surg; 1995 Mar; 1(2):94-8. PubMed ID: 9346547
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of the diagnostic value of Wisteria floribunda agglutinin-sialylated mucin1 and the prognostic role of mucin1 in human cholangiocarcinoma.
Tang Z; Yang Y; Wang X; Meng W; Li X
BMJ Open; 2019 Jan; 9(1):e021693. PubMed ID: 30700476
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
Liang B; Zhong L; He Q; Wang S; Pan Z; Wang T; Zhao Y
Med Sci Monit; 2015 Nov; 21():3555-63. PubMed ID: 26576628
[TBL] [Abstract][Full Text] [Related]
17. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
[TBL] [Abstract][Full Text] [Related]
18. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach.
Le Large TYS; Meijer LL; Paleckyte R; Boyd LNC; Kok B; Wurdinger T; Schelfhorst T; Piersma SR; Pham TV; van Grieken NCT; Zonderhuis BM; Daams F; van Laarhoven HWM; Bijlsma MF; Jimenez CR; Giovannetti E; Kazemier G
Oncologist; 2020 Apr; 25(4):e634-e643. PubMed ID: 31943574
[TBL] [Abstract][Full Text] [Related]
19. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.
Siqueira E; Schoen RE; Silverman W; Martin J; Rabinovitz M; Weissfeld JL; Abu-Elmaagd K; Madariaga JR; Slivka A
Gastrointest Endosc; 2002 Jul; 56(1):40-7. PubMed ID: 12085033
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma.
Leelawat K; Narong S; Wannaprasert J; Ratanashu-ek T
World J Gastroenterol; 2010 Oct; 16(37):4697-703. PubMed ID: 20872971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]